QUANTICA
10.11.2022 11:46:41 CET | Business Wire | Press release
Last November at the international additive manufacturing exhibition Formnext, Quantica announced its T1 Pro, an R&D system that showcased the company’s multi-material, ultra-high viscosity jetting capabilities, known as NovoJet™. A year later, Quantica is back at the Frankfurt-based expo, this time introducing a new Desktop system– the NovoJet™ C-7.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005047/en/
The Berlin-based 3D printing start-up is pushing the boundaries of multi-material and high-performance material jetting, through the introduction of the NovoJet™ C-7. A printer suitable for research, feasibility studies, and small scale production of custom applications. It will be made available to research institutes and industry partners, looking to develop high-performance, multi-material 3D printing and other additive manufacturing applications.
NovoJet™ C-7 is an open printing platform, ideal for 2D and 3D application development using Quantica’s ultra-high viscosity jetting technology. It has been created for research institutes, R&D labs, and organizations looking to develop new additive manufacturing materials and workflows. Beyond feasibility testing and application development, the printer can also be used for customized and low-volume production, enabling a truly seamless transition from lab to production.
Key features of the NovoJet™ C-7 include:
- Material Experimentation: The system uses printheads capable of handling a wide range of fluids with viscosities exceeding 380mPa•s at jetting temperature, equating to approximately 4000mPa•s at ambient temperature. Along with experimentation with liquids with high particle loading.
- New Material Combinations: The system has the ability to control up to 7 material channels giving users access to new material combinations with better mechanical properties, color fidelity, and aesthetics.
- System Customization: The system offers customizable integrations for research and development needs.
The power of Quantica’s NovoJet™ printhead technology is its ability to print materials that are 15 times more viscous than legacy inkjet printheads. This opens up new possibilities for delivering high value end-part products with properties such as high toughness, temperature resistance, conductivity, biocompatibility, and flexibility manufactured in a single process.
Multiple industry partners, mainly within the dental, medical and electronics space, have started collaborations with Quantica to develop targeted solutions based on the novel capabilities.
“This new system unlocks enormous possibilities for the material deposition industries, giving material developers the ability to move past the limitations of low performance fluids and start developing new formulations with better properties of interest. In the end, we empower organizations to build products in new and exciting ways,” said Ramon Borrell, CTO of Quantica. “Quantica is already exploring several applications in the dental, healthcare, consumer goods, and electronics industries. We are excited to support these, and the many other, industries in breaking down current inkjet barriers and limitations.”
For more information about the NovoJet™ C-7, please visit https://quantica3d.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom